3 withdrawn, 2 completed, 2 terminated, 1 active not recruiting. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Withdrawn 3, Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow IC14: new trials by email Literature Review of IC14 trials Research Report on IC14
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients Atibuclimab, Placebo - Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome | Phase 2 | Recruiting | Implicit Bioscience | 56 | 2026-06-17 | 2026-07-29 |
| IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy IC14 - Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy | Phase 1 / Phase 2 | Completed | Implicit Bioscience | 1 | 2024-03-29 | 2026-04-22 |
| IC14 for Treatment of Amyotrophic Lateral Sclerosis IC14, Placebo - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 2 | Withdrawn | Implicit Bioscience | 2021-08-15 | 2026-05-05 | |
| COVID-19 and Anti-CD14 Treatment Trial anti-CD14, Placebo, remdesivir - Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 49 | 2021-04-12 | 2023-06-26 |
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Remdesivir, Imatinib Mesylate, Dexamethasone - COVID-19 | Phase 2 | Active not recruiting | QuantumLeap Healthcare Collaborative | 1500 | 2020-07-31 | 2026-03-16 |
| A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome IC14, Placebo - Acute Respiratory Distress Syndrome | Phase 2 | Withdrawn | Implicit Bioscience | 2019-06-01 | 2026-05-05 | |
| IC14 in Adult Patients With Dengue Fever IC14, Placebo - Dengue Fever | Phase 2 | Withdrawn | Implicit Bioscience | 2019-05-01 | 2026-05-05 | |
| Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease IC14 - Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 1 | Completed | Implicit Bioscience | 10 | 2017-10-01 | 2025-08-20 |
| IC14 Antibodies to Treat Individuals With Acute Lung Injury IC14 - Respiratory Distress Syndrome, Adult, Lung Diseases | Phase 2 | Terminated | University of Washington | 13 | 2005-09-01 | 2017-05-16 |
| IC14 for ALS Patients Expanded Access IC14 - Amyotrophic Lateral Sclerosis | No longer available | Implicit Bioscience | 2025-08-20 |
Respiratory Distress Syndrome (4) · Amyotrophic Lateral Sclerosis (3) · COVID-19 (2) · Motor Neuron Disease (2) · Acute Lung Injury (1) · Arrhythmias, Cardiac (1) · Arrhythmogenic Right Ventricular Dysplasia (1) · Arrhythmogenic Right Ventricular Dysplasia, Familial, 1 (1) · Dengue (1) · Disease (1) · Lung Diseases (1) · Respiratory Insufficiency (1)
Implicit Bioscience (7) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · QuantumLeap Healthcare Collaborative (1) · University of Washington (1)
United States (6) · Australia (2)
Jan Agosti, MD (3) · Derek W Russell, MD (1) · Kathleen D Liu, MD (1) · Laura Esserman, MD (1) · Linzee Mabrey, MD, MsC (1) · Margaret Neff, MD (1) · Mark M. Wurfel, MD, PhD (1) · Robert D Henderson, MBBS (1) · Robert D. Henderson, MBBS (1) · Thomas R. Martin, MD (1)
PMID 34473343, PMID 34678870, PMID 36533976, PMID 36883141, PMID 39592213, PMID 40462830, PMID 42799508
P50HL073996 (1), UM1AI109565 (1)